Page last updated: 2024-08-25

rosiglitazone and alpha-methylhydrocinnamic acid

rosiglitazone has been researched along with alpha-methylhydrocinnamic acid in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dai, B; Fu, L; Jia, J; Li, L; Liu, J; Mei, C; Shen, J; Tang, J; Wang, L; Xiong, X; Ye, Y1
Chen, M; Dai, B; Fu, L; Liu, M; Mei, C; Shen, J; Tang, J; Wang, L; Wang, Q; Xiong, X; Ye, Y1
Fu, L; Gao, X; Hu, H; Jia, J; Li, L; Mei, C; Shen, J; Wang, L; Xiong, X; Ye, Y1

Other Studies

3 other study(ies) available for rosiglitazone and alpha-methylhydrocinnamic acid

ArticleYear
Antitumor activity of a novel series of alpha-aryloxy-alpha-methylhydrocinnamic acid derivatives as PPAR gamma agonists against a panel of human cancer cell lines.
    Investigational new drugs, 2009, Volume: 27, Issue:3

    Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; L-Lactate Dehydrogenase; Phenylpropionates; PPAR gamma; Propidium; Rosiglitazone; Thiazolidinediones

2009
Pyrimidinyl-arylpropionic acid derivatives: viable resources in the development of new antineoplastic agents.
    Investigational new drugs, 2010, Volume: 28, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; Mice; Mice, Nude; Models, Chemical; Phenylpropionates; PPAR gamma; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones; Xenograft Model Antitumor Assays

2010
Antitumor efficacy of two novel non-thiazolidinedione compounds as peroxisome proliferator-activated receptor-gamma agonists in human osteosarcoma cells in vitro.
    Chemotherapy, 2009, Volume: 55, Issue:6

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Osteosarcoma; Phenylpropionates; PPAR gamma; Rosiglitazone; Thiazolidinediones

2009